Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
At present, the global COVID‐19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID‐19, promoting roll‐out vaccinations and building herd immunity are still the most effective and economic measures...
Saved in:
| Published in | Journal of medical virology Vol. 94; no. 6; pp. 2369 - 2375 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.06.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0146-6615 1096-9071 1096-9071 |
| DOI | 10.1002/jmv.27590 |
Cover
| Abstract | At present, the global COVID‐19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID‐19, promoting roll‐out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID‐19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID‐19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high‐risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.
Highlights
At present, the global COVID‐19 epidemic still faces severe challenges.
It is necessary to carry out a booster vaccination strategy, especially for the high‐risk groups.
A heterologous booster can induce higher immune responses than homologous vaccinations. |
|---|---|
| AbstractList | At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies. At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies. At present, the global COVID‐19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID‐19, promoting roll‐out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID‐19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID‐19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high‐risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies. At present, the global COVID‐19 epidemic still faces severe challenges. It is necessary to carry out a booster vaccination strategy, especially for the high‐risk groups. A heterologous booster can induce higher immune responses than homologous vaccinations. At present, the global COVID‐19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID‐19, promoting roll‐out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID‐19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID‐19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high‐risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies. Highlights At present, the global COVID‐19 epidemic still faces severe challenges. It is necessary to carry out a booster vaccination strategy, especially for the high‐risk groups. A heterologous booster can induce higher immune responses than homologous vaccinations. |
| Author | Meng, Hanyan Ye, Qing Mao, Jianhua |
| Author_xml | – sequence: 1 givenname: Hanyan surname: Meng fullname: Meng, Hanyan organization: Zhejiang University School of Medicine – sequence: 2 givenname: Jianhua orcidid: 0000-0002-6076-3806 surname: Mao fullname: Mao, Jianhua email: maojh88@zju.edu.cn organization: Zhejiang University School of Medicine – sequence: 3 givenname: Qing orcidid: 0000-0002-6756-0630 surname: Ye fullname: Ye, Qing email: qingye@zju.edu.cn organization: Zhejiang University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35028946$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kcFO3DAURS0EgoF20R9AkdgUiTDPTuzE7CiiLdW03bTdWo7zgjxKYoidQeHrcZmZzQhWXvjcq6dzj8l-73ok5BOFSwrA5studckKLmGPzChIkUoo6D6ZAc1FKgTlR-TY-yUAlJKxQ3KUcWClzMWMmC_O-YBDstLG2F4H6_rEh0EHvJ-ukl9o0HsbpovEdt3Y2-c14aolmmBX6Hc-ttGLRPd14nWDYfpADhrdevy4eU_I36-3f26-p4vf3-5urhepyamEFCmFChoodFVoSYUoua5oQbnJTMWhiadrXmV5oZssg4JzyWtKsUbNaiFrzE7I53Xvw-AeR_RBddYbbFvdoxu9YoIBFGVesoie7aBLNw59vC5SUU5WRlWROt1QY9VhrR4G2-lhUlt9EZivATM47wdslLHhVUTUYFtFQf0fSMWB1OtAMXG-k9iWvsVu2p9si9P7oPrx89868QKA_5_o |
| CitedBy_id | crossref_primary_10_4103_ijmr_ijmr_3330_21 crossref_primary_10_3390_vaccines10111849 crossref_primary_10_1038_s41586_022_05398_2 crossref_primary_10_3390_ijms231911411 crossref_primary_10_1111_1756_185X_14349 crossref_primary_10_1080_21645515_2022_2139098 crossref_primary_10_3389_fpubh_2023_1165611 crossref_primary_10_3390_vaccines11091472 crossref_primary_10_3389_fmed_2022_949554 crossref_primary_10_1016_j_tmaid_2022_102514 crossref_primary_10_1007_s40121_022_00683_z crossref_primary_10_1039_D3TB02895J crossref_primary_10_1002_jmv_27798 crossref_primary_10_1016_j_vaccine_2024_05_070 crossref_primary_10_3390_vaccines11081365 crossref_primary_10_3389_fphar_2023_1053814 crossref_primary_10_1038_s41598_022_16759_2 crossref_primary_10_1080_21645515_2024_2363068 crossref_primary_10_1002_jmv_28292 crossref_primary_10_3390_healthcare11010058 crossref_primary_10_1016_j_vaccine_2022_12_025 crossref_primary_10_1038_s41591_023_02282_y crossref_primary_10_3390_pathogens12050688 crossref_primary_10_1080_21645515_2023_2261201 |
| Cites_doi | 10.1093/infdis/jiab635 10.1002/ehf2.12960 10.1016/S2213-2600(21)00357-X 10.1182/blood.2021011904 10.1016/S0140-6736(21)00628-0 10.1016/S1473-3099(20)30831-8 10.1016/S0140-6736(20)32661-1 10.1111/ajt.16516 10.1186/s40249-021-00915-3 10.1016/S0140-6736(21)01429-X 10.1056/NEJMoa2107659 10.1111/dom.14124 10.1038/s41586-021-03681-2 10.1038/s41591-021-01560-x 10.1016/S0140-6736(21)01420-3 10.1016/j.vaccine.2021.10.038 10.1080/22221751.2021.1957401 10.1038/d41586-021-02158-6 10.1001/jama.2021.8565 10.1001/jama.2021.15072 10.3201/eid2712.211634 10.1016/j.jinf.2020.03.037 10.1038/s41467-021-24909-9 10.1111/j.1365-2567.2007.02555.x 10.1056/NEJMoa2113017 10.1016/j.cmi.2021.11.014 10.3390/jcm10173817 10.1056/NEJMoa2103055 10.1111/ajt.16818 10.1136/bmj.n2814 10.1038/s41467-021-27063-4 10.1038/s41591-021-01377-8 10.1001/jama.2021.19885 10.1056/NEJMoa2101544 10.7150/ijbs.59374 10.1016/S0140-6736(21)00501-8 10.1002/jmv.26036 10.1016/j.cell.2020.06.008 10.1001/jamacardio.2021.2828 10.1002/ajh.26185 10.1016/j.chom.2021.01.014 10.1056/NEJMoa2035389 10.1056/NEJMoa2107715 10.1038/s41467-021-23173-1 10.1136/bmj.n2160 10.1038/d41573-020-00073-5 10.1093/cid/ciab996 10.1056/NEJMc2108861 10.1080/14760584.2021.1971522 10.1542/peds.2020-0702 10.1038/s41586-021-04120-y 10.1056/NEJMc2032195 10.1056/NEJMoa2110345 10.15585/mmwr.mm7027e2 10.1016/S0140-6736(21)02249-2 10.1016/S0140-6736(20)31605-6 10.1093/infdis/jiab556 10.1056/NEJMc2036242 10.1016/S0140-6736(21)01642-1 10.1056/NEJMoa2102214 10.3389/fimmu.2021.646333 10.3390/vaccines9101163 10.1016/S0140-6736(21)00234-8 10.1016/j.vaccine.2021.10.007 10.1126/science.372.6547.1138 10.1016/j.smim.2021.101507 10.1038/s41422-021-00590-x |
| ContentType | Journal Article |
| Copyright | 2022 Wiley Periodicals LLC 2022 Wiley Periodicals LLC. |
| Copyright_xml | – notice: 2022 Wiley Periodicals LLC – notice: 2022 Wiley Periodicals LLC. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
| DOI | 10.1002/jmv.27590 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Genetics Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1096-9071 |
| EndPage | 2375 |
| ExternalDocumentID | 35028946 10_1002_jmv_27590 JMV27590 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 K9. M7N P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c4190-e110b0f07ab7a916685ab1715c3cb50f922a5b347af33075595d11edea2d69de3 |
| IEDL.DBID | DR2 |
| ISSN | 0146-6615 1096-9071 |
| IngestDate | Fri Jul 11 16:22:22 EDT 2025 Sat Jul 26 02:23:22 EDT 2025 Thu Apr 03 07:07:35 EDT 2025 Tue Jul 01 02:24:52 EDT 2025 Thu Apr 24 23:01:36 EDT 2025 Wed Jan 22 16:26:08 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | COVID-19 booster vaccination SARS-CoV-2 vaccine heterologous vaccination |
| Language | English |
| License | 2022 Wiley Periodicals LLC. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4190-e110b0f07ab7a916685ab1715c3cb50f922a5b347af33075595d11edea2d69de3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-6076-3806 0000-0002-6756-0630 |
| PMID | 35028946 |
| PQID | 2650238089 |
| PQPubID | 105515 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2620078482 proquest_journals_2650238089 pubmed_primary_35028946 crossref_citationtrail_10_1002_jmv_27590 crossref_primary_10_1002_jmv_27590 wiley_primary_10_1002_jmv_27590_JMV27590 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2022 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | Journal of medical virology |
| PublicationTitleAlternate | J Med Virol |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2021; 9 2021; 27 2021; 6 2021; 21 2021; 20 2021; 323 2021; 29 2021; 326 2021; 600 2020; 182 2020; 80 2007; 120 2021; 384 2020; 145 2021; 385 2021; 96 2020; 19 2021; 70 2020; 7 2021; 13 2021; 10 2021; 12 2021; 55 2021; 398 2022; 60 2022 2021; 596 2021 2020; 396 2021; 137 2021; 17 2021; 39 2020; 92 2021; 591 2021; 372 2021; 375 2021; 397 2020; 22 2022; 32 2021; 374 2021; 84 2022; 225 e_1_2_11_70_1 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 e_1_2_11_2_1 e_1_2_11_60_1 Gaebler C (e_1_2_11_7_1) 2021; 591 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_66_1 e_1_2_11_47_1 e_1_2_11_68_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_64_1 Zhang X (e_1_2_11_49_1) 2021; 323 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_59_1 e_1_2_11_38_1 e_1_2_11_19_1 Salvagno GL (e_1_2_11_13_1) 2022; 60 e_1_2_11_50_1 e_1_2_11_71_1 Tian D (e_1_2_11_10_1) 2021; 84 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_58_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_61_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_18_1 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 Malayala SV (e_1_2_11_72_1) 2021; 13 |
| References_xml | – volume: 384 start-page: 1885 issue: 20 year: 2021 end-page: 1898 article-title: Efficacy of the ChAdOx1 nCoV‐19 Covid‐19 vaccine against the B.1.351 variant publication-title: N Engl J Med – volume: 398 start-page: 385 issue: 10298 year: 2021 end-page: 387 article-title: Spike‐antibody waning after second dose of BNT162b2 or ChAdOx1 publication-title: Lancet – volume: 96 start-page: E257 issue: 7 year: 2021 end-page: E259 article-title: Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine publication-title: Am J Hematol – volume: 92 start-page: 1818 issue: 10 year: 2020 end-page: 1824 article-title: Hepatic complications of COVID‐19 and its treatment publication-title: J Med Virol – volume: 397 start-page: 99 issue: 10269 year: 2021 end-page: 111 article-title: Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine (AZD1222) against SARS‐CoV‐2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet – volume: 385 start-page: 1761 issue: 19 year: 2021 end-page: 1773 article-title: Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine through 6 months publication-title: N Engl J Med – volume: 12 start-page: 4598 issue: 1 year: 2021 article-title: Neutralizing activity of sputnik V vaccine sera against SARS‐CoV‐2 variants publication-title: Nat Commun – volume: 372 start-page: 1138 issue: 6547 year: 2021 article-title: Mixing vaccines may boost immune responses publication-title: Science – volume: 385 start-page: 875 issue: 10 year: 2021 end-page: 884 article-title: Effectiveness of an Inactivated SARS‐CoV‐2 vaccine in Chile publication-title: N Engl J Med – volume: 10 start-page: 1598 issue: 1 year: 2021 end-page: 1608 article-title: Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS‐CoV‐2 vaccine publication-title: Emerg Microbes Infect – volume: 384 start-page: 80 issue: 1 year: 2021 end-page: 82 article-title: Durability of responses after SARS‐CoV‐2 mRNA‐1273 vaccination publication-title: N Engl J Med – volume: 12 issue: 1 year: 2021 article-title: Protective mucosal immunity against SARS‐CoV‐2 after heterologous systemic prime‐mucosal boost immunization publication-title: Nat Commun – volume: 182 start-page: 713 issue: 3 year: 2020 end-page: 721 article-title: Development of an inactivated vaccine candidate, BBIBP‐CorV, with potent protection against SARS‐CoV‐2 publication-title: Cell – volume: 84 year: 2021 article-title: The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape publication-title: J Med Virol – volume: 397 start-page: 671 issue: 10275 year: 2021 end-page: 681 article-title: Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector‐based heterologous prime‐boost COVID‐19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet – volume: 7 start-page: 3464 issue: 6 year: 2020 end-page: 3472 article-title: Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment publication-title: ESC Heart Fail – volume: 39 start-page: 6713 issue: 46 year: 2021 end-page: 6719 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP‐CorV‐vaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon publication-title: Vaccine – volume: 22 start-page: 1915 issue: 10 year: 2020 end-page: 1924 article-title: Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: a systematic review and meta‐analysis publication-title: Diabetes Obes Metab – volume: 384 start-page: 1899 issue: 20 year: 2021 end-page: 1909 article-title: Efficacy of NVX‐CoV2373 Covid‐19 vaccine against the B.1.351 variant publication-title: N Engl J Med – volume: 326 start-page: 1390 issue: 14 year: 2021 end-page: 1399 article-title: Surveillance for adverse events after COVID‐19 mRNA vaccination publication-title: JAMA – volume: 27 start-page: 1874 issue: 11 year: 2021 end-page: 1875 article-title: Boosting immunity to COVID‐19 vaccines publication-title: Nat Med – volume: 10 start-page: 3817 issue: 17 year: 2021 article-title: An immunogenicity report for the comparison between heterologous and homologous prime‐boost schedules with ChAdOx1‐S and BNT162b2 vaccines publication-title: J Clin Med – volume: 13 issue: 10 year: 2021 article-title: A case of idiopathic thrombocytopenic purpura after booster dose of BNT162b2 (Pfizer‐Biontech) COVID‐19 vaccine publication-title: Cureus – volume: 10 start-page: 132 issue: 1 year: 2021 article-title: Effectiveness and safety of SARS‐CoV‐2 vaccine in real‐world studies: a systematic review and meta‐analysis publication-title: Infect Dis Poverty – volume: 600 start-page: 701 issue: 7890 year: 2021 end-page: 706 article-title: Immunogenicity and efficacy of heterologous ChAdOx1‐BNT162b2 vaccination publication-title: Nature – volume: 39 start-page: 6984 issue: 48 year: 2021 end-page: 6989 article-title: COVID‐19 vaccine—long term immune decline and breakthrough infections publication-title: Vaccine – volume: 60 start-page: e29 issue: 2 year: 2022 end-page: e31 article-title: The pronounced decline of anti‐SARS‐CoV‐2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters publication-title: Clin Chem Lab Med – volume: 12 year: 2021 article-title: Cellular immune response to COVID‐19 and potential immune modulators publication-title: Front Immunol – volume: 6 start-page: 1196 issue: 10 year: 2021 end-page: 1201 article-title: Patients with acute myocarditis following mRNA COVID‐19 vaccination publication-title: JAMA Cardiol – volume: 55 year: 2021 article-title: Heterologous humoral immunity to human and zoonotic coronaviruses: aiming for the Achilles heel publication-title: Semin Immunol – year: 2021 article-title: Host predictors of broadly cross‐reactive antibodies against SARS‐CoV‐2 variants of concern differ between infection and vaccination publication-title: Clin Infect Dis – volume: 384 start-page: 403 issue: 5 year: 2021 end-page: 416 article-title: Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine publication-title: N Engl J Med – volume: 384 start-page: 1576 issue: 16 year: 2021 end-page: 1577 article-title: Safety and efficacy of the BNT162b2 mRNA Covid‐19 Vaccine publication-title: N Engl J Med – year: 2021 article-title: Immunogenicity trends one and three months after second BNT162B2 vaccination among healthcare workers in Israel publication-title: Clin Microbiol Infect – volume: 385 start-page: 1172 issue: 13 year: 2021 end-page: 1183 article-title: Safety and efficacy of NVX‐CoV2373 Covid‐19 vaccine publication-title: N Engl J Med – volume: 21 start-page: 1332 issue: 3 year: 2021 end-page: 1337 article-title: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine—United States, December 14‐23, 2020 publication-title: Am J Transplant – volume: 398 start-page: 2093 issue: 10316 year: 2021 end-page: 2100 article-title: Effectiveness of a third dose of the BNT162b2 mRNA COVID‐19 vaccine for preventing severe outcomes in Israel: an observational study publication-title: Lancet – volume: 20 start-page: 1211 issue: 10 year: 2021 end-page: 1220 article-title: To mix or not to mix? A rapid systematic review of heterologous prime‐boost covid‐19 vaccination publication-title: Expert Rev Vaccines – volume: 80 start-page: 607 issue: 6 year: 2020 end-page: 613 article-title: The pathogenesis and treatment of the “Cytokine Storm” in COVID‐19 publication-title: J Infect – volume: 398 start-page: 213 issue: 10296 year: 2021 end-page: 222 article-title: Efficacy and safety of an inactivated whole‐virion SARS‐CoV‐2 vaccine (CoronaVac): interim results of a double‐blind, randomised, placebo‐controlled, phase 3 trial in Turkey publication-title: Lancet – volume: 9 start-page: 1255 issue: 11 year: 2021 end-page: 1265 article-title: Safety, reactogenicity, and immunogenicity of homologous and heterologous prime‐boost immunisation with ChAdOx1 nCoV‐19 and BNT162b2: a prospective cohort study publication-title: Lancet Respir Med – volume: 397 start-page: 1057 issue: 10279 year: 2021 end-page: 1058 article-title: Antibody response to first BNT162b2 dose in previously SARS‐CoV‐2‐infected individuals publication-title: Lancet – volume: 137 start-page: 3674 issue: 26 year: 2021 end-page: 3676 article-title: Low neutralizing antibody responses against SARS‐CoV‐2 in older patients with myeloma after the first BNT162b2 vaccine dose publication-title: Blood – volume: 32 start-page: 103 issue: 1 year: 2022 end-page: 106 article-title: Recombinant protein subunit vaccine booster following two‐dose inactivated vaccines dramatically enhanced anti‐RBD responses and neutralizing titers against SARS‐CoV‐2 and variants of concern publication-title: Cell Res – year: 2022 article-title: SARS‐CoV‐2 variant exposures elicit antibody responses with differential cross‐neutralization of established and emerging strains including Delta and Omicron publication-title: J Infect Dis – volume: 323 start-page: 1843 year: 2021 article-title: Advances in laboratory detection methods and technology application of SARS‐CoV‐2 publication-title: J Med Virol – volume: 21 start-page: 39 issue: 1 year: 2021 end-page: 51 article-title: Safety and immunogenicity of an inactivated SARS‐CoV‐2 vaccine, BBIBP‐CorV: a randomised, double‐blind, placebo‐controlled, phase 1/2 trial publication-title: Lancet Infect Dis – volume: 396 start-page: 479 issue: 10249 year: 2020 end-page: 488 article-title: Immunogenicity and safety of a recombinant adenovirus type‐5‐vectored COVID‐19 vaccine in healthy adults aged 18 years or older: a randomised, double‐blind, placebo‐controlled, phase 2 trial publication-title: Lancet – volume: 225 start-page: 30 issue: 1 year: 2022 end-page: 33 article-title: Effectiveness of a third dose of BNT162b2 mRNA vaccine publication-title: J Infect Dis – volume: 397 start-page: 1351 issue: 10282 year: 2021 end-page: 1362 article-title: Efficacy of ChAdOx1 nCoV‐19 (AZD1222) vaccine against SARS‐CoV‐2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial publication-title: Lancet – volume: 12 start-page: 2893 issue: 1 year: 2021 article-title: Heterologous vaccination regimens with self‐amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice publication-title: Nat Commun – volume: 398 start-page: 121 issue: 10295 year: 2021 end-page: 130 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1‐S‐primed participants (CombiVacS): a multicentre, open‐label, randomised, controlled, phase 2 trial publication-title: Lancet – volume: 145 issue: 6 year: 2020 article-title: Epidemiology of COVID‐19 among children in China publication-title: Pediatrics – volume: 17 start-page: 1119 issue: 4 year: 2021 end-page: 1124 article-title: Assessment of global asymptomatic SARS‐CoV‐2 infection and management practices from China publication-title: Int J Biol Sci – volume: 596 start-page: 268 issue: 7871 year: 2021 end-page: 272 article-title: Immunogenicity of Ad26.COV2.S vaccine against SARS‐CoV‐2 variants in humans publication-title: Nature – volume: 385 start-page: 661 issue: 7 year: 2021 end-page: 662 article-title: Three doses of an mRNA Covid‐19 vaccine in solid‐organ transplant recipients publication-title: N Engl J Med – volume: 375 start-page: n2814 year: 2021 article-title: Covid‐19: booster vaccine gives “significant increased protection” in over 50s publication-title: BMJ – volume: 120 start-page: 435 issue: 4 year: 2007 end-page: 446 article-title: Immunosenescence: emerging challenges for an ageing population publication-title: Immunology – volume: 29 start-page: 477 issue: 3 year: 2021 end-page: 488 article-title: Identification of SARS‐CoV‐2 spike mutations that attenuate monoclonal and serum antibody neutralization publication-title: Cell Host Microbe – volume: 21 start-page: 3990 issue: 12 year: 2021 end-page: 4002 article-title: Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector‐based COVID‐19 vaccine regimens in solid organ transplant recipients publication-title: Am J Transplant – volume: 596 start-page: 178 issue: 7871 year: 2021 end-page: 180 article-title: COVID vaccine boosters: the most important questions publication-title: Nature – volume: 384 start-page: 2187 issue: 23 year: 2021 end-page: 2201 article-title: Safety and efficacy of single‐dose Ad26.COV2.S vaccine against Covid‐19 publication-title: N Engl J Med – volume: 326 start-page: 35 issue: 1 year: 2021 end-page: 45 article-title: Effect of 2 inactivated SARS‐CoV‐2 vaccines on symptomatic COVID‐19 infection in adults: a randomized clinical trial publication-title: JAMA – volume: 374 start-page: n2160 year: 2021 article-title: Covid‐19: UK will offer third vaccine dose to severely immunosuppressed people publication-title: BMJ – volume: 9 start-page: 1163 issue: 10 year: 2021 article-title: The effects of heterologous immunization with prime‐boost COVID‐19 vaccination against SARS‐CoV‐2 publication-title: Vaccines (Basel) – volume: 591 start-page: 639 issue: 7851 year: 2021 end-page: 644 article-title: Evolution of antibody immunity to SARS‐CoV‐2 publication-title: bioRxiv – volume: 326 start-page: 2203 issue: 21 year: 2021 end-page: 2204 article-title: Antibody titers before and after a third dose of the SARS‐CoV‐2 BNT162b2 vaccine in adults aged ≥60 years publication-title: JAMA – volume: 27 start-page: 1205 issue: 7 year: 2021 end-page: 1211 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS‐CoV‐2 infection publication-title: Nat Med – volume: 70 start-page: 977 issue: 27 year: 2021 end-page: 982 article-title: Use of mRNA COVID‐19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices—United States, June 2021 publication-title: MMWR Morb Mortal Wkly Rep – volume: 19 start-page: 305 issue: 5 year: 2020 end-page: 306 article-title: The COVID‐19 vaccine development landscape publication-title: Nat Rev Drug Discov – volume: 385 start-page: 1774 issue: 19 year: 2021 end-page: 1785 article-title: Efficacy of the mRNA‐1273 SARS‐CoV‐2 vaccine at completion of blinded phase publication-title: N Engl J Med – volume: 27 start-page: 3175 issue: 12 year: 2021 end-page: 3178 article-title: Guillain‐Barre syndrome associated with COVID‐19 vaccination publication-title: Emerg Infect Dis – ident: e_1_2_11_20_1 doi: 10.1093/infdis/jiab635 – ident: e_1_2_11_66_1 doi: 10.1002/ehf2.12960 – ident: e_1_2_11_71_1 doi: 10.1016/S2213-2600(21)00357-X – ident: e_1_2_11_45_1 doi: 10.1182/blood.2021011904 – ident: e_1_2_11_37_1 doi: 10.1016/S0140-6736(21)00628-0 – ident: e_1_2_11_25_1 doi: 10.1016/S1473-3099(20)30831-8 – ident: e_1_2_11_36_1 doi: 10.1016/S0140-6736(20)32661-1 – ident: e_1_2_11_69_1 doi: 10.1111/ajt.16516 – ident: e_1_2_11_11_1 doi: 10.1186/s40249-021-00915-3 – ident: e_1_2_11_23_1 doi: 10.1016/S0140-6736(21)01429-X – ident: e_1_2_11_32_1 doi: 10.1056/NEJMoa2107659 – ident: e_1_2_11_41_1 doi: 10.1111/dom.14124 – ident: e_1_2_11_30_1 doi: 10.1038/s41586-021-03681-2 – ident: e_1_2_11_19_1 doi: 10.1038/s41591-021-01560-x – ident: e_1_2_11_70_1 doi: 10.1016/S0140-6736(21)01420-3 – ident: e_1_2_11_12_1 doi: 10.1016/j.vaccine.2021.10.038 – ident: e_1_2_11_58_1 doi: 10.1080/22221751.2021.1957401 – ident: e_1_2_11_73_1 doi: 10.1038/d41586-021-02158-6 – ident: e_1_2_11_26_1 doi: 10.1001/jama.2021.8565 – ident: e_1_2_11_64_1 doi: 10.1001/jama.2021.15072 – ident: e_1_2_11_63_1 doi: 10.3201/eid2712.211634 – ident: e_1_2_11_68_1 doi: 10.1016/j.jinf.2020.03.037 – ident: e_1_2_11_39_1 doi: 10.1038/s41467-021-24909-9 – ident: e_1_2_11_46_1 doi: 10.1111/j.1365-2567.2007.02555.x – ident: e_1_2_11_28_1 doi: 10.1056/NEJMoa2113017 – ident: e_1_2_11_43_1 doi: 10.1016/j.cmi.2021.11.014 – ident: e_1_2_11_54_1 doi: 10.3390/jcm10173817 – ident: e_1_2_11_33_1 doi: 10.1056/NEJMoa2103055 – volume: 591 start-page: 639 issue: 7851 year: 2021 ident: e_1_2_11_7_1 article-title: Evolution of antibody immunity to SARS‐CoV‐2 publication-title: bioRxiv – ident: e_1_2_11_55_1 doi: 10.1111/ajt.16818 – ident: e_1_2_11_15_1 doi: 10.1136/bmj.n2814 – ident: e_1_2_11_61_1 doi: 10.1038/s41467-021-27063-4 – ident: e_1_2_11_6_1 doi: 10.1038/s41591-021-01377-8 – ident: e_1_2_11_18_1 doi: 10.1001/jama.2021.19885 – ident: e_1_2_11_31_1 doi: 10.1056/NEJMoa2101544 – ident: e_1_2_11_3_1 doi: 10.7150/ijbs.59374 – ident: e_1_2_11_40_1 doi: 10.1016/S0140-6736(21)00501-8 – ident: e_1_2_11_67_1 doi: 10.1002/jmv.26036 – ident: e_1_2_11_24_1 doi: 10.1016/j.cell.2020.06.008 – ident: e_1_2_11_65_1 doi: 10.1001/jamacardio.2021.2828 – ident: e_1_2_11_44_1 doi: 10.1002/ajh.26185 – ident: e_1_2_11_9_1 doi: 10.1016/j.chom.2021.01.014 – ident: e_1_2_11_4_1 doi: 10.1056/NEJMoa2035389 – ident: e_1_2_11_22_1 doi: 10.1056/NEJMoa2107715 – ident: e_1_2_11_57_1 doi: 10.1038/s41467-021-23173-1 – volume: 60 start-page: e29 issue: 2 year: 2022 ident: e_1_2_11_13_1 article-title: The pronounced decline of anti‐SARS‐CoV‐2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters publication-title: Clin Chem Lab Med – ident: e_1_2_11_48_1 doi: 10.1136/bmj.n2160 – ident: e_1_2_11_2_1 doi: 10.1038/d41573-020-00073-5 – ident: e_1_2_11_21_1 doi: 10.1093/cid/ciab996 – ident: e_1_2_11_47_1 doi: 10.1056/NEJMc2108861 – ident: e_1_2_11_56_1 doi: 10.1080/14760584.2021.1971522 – volume: 84 year: 2021 ident: e_1_2_11_10_1 article-title: The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape publication-title: J Med Virol – ident: e_1_2_11_42_1 doi: 10.1542/peds.2020-0702 – ident: e_1_2_11_53_1 doi: 10.1038/s41586-021-04120-y – ident: e_1_2_11_8_1 doi: 10.1056/NEJMc2032195 – ident: e_1_2_11_35_1 doi: 10.1056/NEJMoa2110345 – ident: e_1_2_11_62_1 doi: 10.15585/mmwr.mm7027e2 – ident: e_1_2_11_17_1 doi: 10.1016/S0140-6736(21)02249-2 – ident: e_1_2_11_27_1 doi: 10.1016/S0140-6736(20)31605-6 – ident: e_1_2_11_16_1 doi: 10.1093/infdis/jiab556 – ident: e_1_2_11_34_1 doi: 10.1056/NEJMc2036242 – volume: 13 issue: 10 year: 2021 ident: e_1_2_11_72_1 article-title: A case of idiopathic thrombocytopenic purpura after booster dose of BNT162b2 (Pfizer‐Biontech) COVID‐19 vaccine publication-title: Cureus – ident: e_1_2_11_5_1 doi: 10.1016/S0140-6736(21)01642-1 – ident: e_1_2_11_38_1 doi: 10.1056/NEJMoa2102214 – ident: e_1_2_11_14_1 doi: 10.3389/fimmu.2021.646333 – ident: e_1_2_11_50_1 doi: 10.3390/vaccines9101163 – volume: 323 start-page: 1843 year: 2021 ident: e_1_2_11_49_1 article-title: Advances in laboratory detection methods and technology application of SARS‐CoV‐2 publication-title: J Med Virol – ident: e_1_2_11_29_1 doi: 10.1016/S0140-6736(21)00234-8 – ident: e_1_2_11_59_1 doi: 10.1016/j.vaccine.2021.10.007 – ident: e_1_2_11_51_1 doi: 10.1126/science.372.6547.1138 – ident: e_1_2_11_52_1 doi: 10.1016/j.smim.2021.101507 – ident: e_1_2_11_60_1 doi: 10.1038/s41422-021-00590-x |
| SSID | ssj0008922 |
| Score | 2.4900763 |
| SecondaryResourceType | review_article |
| Snippet | At present, the global COVID‐19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no... At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2369 |
| SubjectTerms | Aged Antibodies Antibodies, Neutralizing Antibodies, Viral booster vaccination COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Disease control Epidemics Herd immunity heterologous vaccination Homology Humans Immune response Immunization Immunization, Secondary Immunodeficiency Pandemics Risk groups Safety SARS-CoV-2 Strategy Vaccination vaccine Vaccines Viral diseases Virology |
| Title | Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27590 https://www.ncbi.nlm.nih.gov/pubmed/35028946 https://www.proquest.com/docview/2650238089 https://www.proquest.com/docview/2620078482 |
| Volume | 94 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9UwFD8hPBBfVFD0ApJqfPCBXbauXTd94kNCSC4PRggPJks_E1B2DbuXBP56T9ttBJDE-LIs62nWtefj13bnV4CPQnha8pQnGExtwpgxSSVTvFgqKC1dqpxfh5wcF4cn7OiMny3Alz4XJvJDDAtu3jKCv_YGLlW7fUcaenF5PaaCV36-nuWF583f_3ZHHVVWcQcBPUGCMYj3rEIp3R5q3o9FjwDmfbwaAs7BC_jRNzX-Z_JzPJ-psb59wOL4n9_yEp53QJTsRM1ZhgXbrMDSpNtqfwV6d-rzP67ItdT4JAwgaSOX7c1ncmx9fgFC-C1yHlJMYjonmaqL6ELbBwV91S0iG0Na6ezs5jWcHHz9vneYdCcyJJr5nHOLYEGlLhVSCYnAsii5VJnIuM614qnDPpdc5UxIl6PzwNkKN1lmjZXUFJWx-SosNtPGvgXCuMlZ5XjulGJCSVnyotTGaueqiqXlCD71Y1Prjq7cn5rxq45Ey7TGTqtDp43gwyD6O3J0_E1oox_gujPTtqaITxGzoLKM4P1QjAbmd01kY6dzL-OXc0tW0hG8iYoxvCXnfqOWFdjYMLxPv74-mpyGm7V_F12HZ9QnW4Q1nw1YnF3N7TuEQDO1GXT9D6kuApk |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkGgv0DcLtHWrHnogS9ax46TqBVDRlrJ7qKDiUkV-SuWRRewuEv31HdtJELSVql6iKB4rjh8zn2cynwHeCeFpyVOeoDG1CWPGJKVM8WKpoLRwqXLeDzka58NjdnDCTxbgY5sLE_khOoebXxlBX_sF7h3S27esoacX130qeIkb9qUQn_OQ6OsteVRRxhgC6oIErRBveYVSut1VvWuNfoOYdxFrMDn7q_C9bWz80-SsP5-pvv55j8fxf7_mEaw0WJTsxMnzGBZs_QSWR020_Sno3YlPAbki11LjkzCGZBrpbG8-kLH1KQaI4rfIj5BlEjM6yUSdRi06vVfQVt0isjZkKp2d3TyD4_1PR3vDpDmUIdHMp51bxAsqdamQSkjElnnBpRqIAdeZVjx12OmSq4wJ6TLUH7hh4WYwsMZKavLS2Ow5LNaT2q4BYdxkrHQ8c0oxoaQseF5oY7VzZcnSogfv28GpdMNY7g_OOK8i1zKtsNOq0Gk9eNuJXkaajj8JbbYjXDUrdVpRhKgIW3C29OBNV4xrzAdOZG0ncy_jPboFK2gPXsSZ0b0l4z5Wy3JsbBjfv7--Ohh9Czfr_y76Gh4Mj0aH1eHn8ZcNeEh97kVwAW3C4uxqbl8iIpqpV2Hi_wLLGAa3 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9UwFD8hmBBfRPziKmg1PvjALrtdu27wJOANovfGGDE8kCz9TETdJdx7SeCv57TdRkBMjC_LsrZZ156PX3t2fgV4K4SnJU95gs7UJowZk5QyxYulgtLCpcr5fcjRON8_ZAdH_GgBtttcmMgP0W24ec0I9tor-Klxm9ekoSe_z_tU8BLX6_dYjm7SI6Kv19xRRRlDCGgKEnRCvKUVSulm1_SmM_oDYd4ErMHjDJfhuO1r_NHkZ38-U319eYvG8T8_5iE8aJAoeR9FZwUWbP0IlkZNrP0x6J2JTwA5I-dS45Mwg2QayWwvtsjY-gQDxPAb5EfIMYn5nGSiTqINnd4qaJtuEFkbMpXOzi6ewOHww7fd_aQ5kiHRzCedW0QLKnWpkEpIRJZ5waUaiAHXmVY8dTjmkquMCekytB64XOFmMLDGSmry0tjsKSzWk9quAmHcZKx0PHNKMaGkLHheaGO1c2XJ0qIH79q5qXTDV-6PzfhVRaZlWuGgVWHQevCmq3oaSTruqrTWTnDV6Om0oghQEbSgsPTgdVeMGubDJrK2k7mv4_dzC1bQHjyLgtG9JeM-Usty7GyY3r-_vjoYfQ83z_-96itY-rI3rD5_HH96AfepT7wI-z9rsDg7m9t1hEMz9TKI_RW6IQVm |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Booster+vaccination+strategy%3A+Necessity%2C+immunization+objectives%2C+immunization+strategy%2C+and+safety&rft.jtitle=Journal+of+medical+virology&rft.au=Meng%2C+Hanyan&rft.au=Mao%2C+Jianhua&rft.au=Ye%2C+Qing&rft.date=2022-06-01&rft.issn=1096-9071&rft.eissn=1096-9071&rft.volume=94&rft.issue=6&rft.spage=2369&rft_id=info:doi/10.1002%2Fjmv.27590&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |